

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 64

Published online August 30, 2022

Online  
Article

IN THIS ISSUE

Novavax Vaccine Authorized for Adolescents 12-17 Years Old

### Important Copyright Message

**FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS**

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 64

Published online August 30, 2022

Online  
Article

### IN THIS ISSUE

**COVID-19 Update: Novavax Vaccine Authorized for Adolescents 12-17 Years Old**

### COVID-19 Update

#### Novavax Vaccine Authorized for Adolescents 12-17 Years Old

The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include use of the vaccine as a two-dose primary series in adolescents 12-17 years old.<sup>1</sup> The vaccine was authorized for primary immunization of adults in July 2022.<sup>2</sup>

**CLINICAL STUDIES** – Expansion of the EUA was based on the results of a study (summarized in the FDA Fact Sheet) comparing the immunogenicity of two Novavax vaccine doses given 3 weeks apart in 390 adolescents 12-17 years old with that in 415 adults 18-25 years old. At 14 days after the second dose, the geometric mean anti-SARS-CoV-2 neutralizing antibody titer level was higher in the adolescent group than among the young adults (3859.6 vs 2611.8; geometric mean ratio 1.47 [95% CI 1.26-1.72]), and 99% of adolescents had experienced a seroresponse.<sup>3</sup>

In an observer-blind trial (PREVENT-19 expansion; summarized in the FDA Fact Sheet), 2247 adolescents 12-17 years old were randomized 2:1 to receive the Novavax vaccine or placebo at 0 and 3 weeks. Immunocompromised persons and those with a history of SARS-CoV-2 infection were excluded. In a descriptive per-protocol efficacy analysis in 1799 adolescents, PCR-confirmed COVID-19 with onset  $\geq 7$  days after the second dose was found to have occurred in 5 subjects who received the vaccine and

in 11 who received placebo; the vaccine efficacy rate was 78.3% (95% CI 37.6%-92.5%). All COVID-19 cases in both groups were mild in severity, and all genetically sequenced cases were caused by the Delta variant of SARS-CoV-2.<sup>3</sup>

**ADVERSE EFFECTS** – Adverse effects of the Novavax vaccine in adolescents appear to be similar to those in adults. In the PREVENT-19 expansion, the most common severe adverse effects after the second vaccine dose were injection-site pain/tenderness (7.7%) and systemic myalgia (7.5%). Myocarditis occurred in one adolescent who received the vaccine.<sup>3</sup>

**DOSAGE AND ADMINISTRATION** – The FDA-approved dosage of the Novavax vaccine for primary immunization in adolescents is 0.5 mL (5 mcg of vaccine with 50 mcg of adjuvant) injected intramuscularly at 0 and 3 weeks, the same as that in adults.<sup>3</sup> According to the CDC, an 8-week interval between doses may be optimal for immunocompetent adolescents, especially males, to reduce the small risk of myocarditis/pericarditis.<sup>4</sup> ■

1. FDA News Release. FDA roundup: August 19, 2022. Available at: <https://bit.ly/3dKGxmt>. Accessed August 30, 2022.
2. COVID-19 update: FDA authorizes Novavax COVID-19 vaccine. *Med Lett Drugs Ther* 2022; 64:121.
3. FDA. Fact sheet for health care providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Novavax COVID-19 vaccine, adjuvanted to prevent coronavirus disease 2019 (COVID-19). August 19, 2022. Available at: <https://bit.ly/3o702aV>. Accessed August 30, 2022.
4. CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. August 22, 2022. Available at: <https://bit.ly/3KgPdxl>. Accessed August 30, 2022.

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

#### Address:

The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
www.medicalletter.org

#### Customer Service:

Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: custserv@medicalletter.org

#### Permissions:

To reproduce any portion of this issue,  
please e-mail your request to:  
permissions@medicalletter.org

#### Subscriptions (US):

1 year - \$159; 2 years - \$298;  
3 years - \$398. \$65 per year  
for students, interns, residents,  
and fellows in the US and Canada.  
Reprints - \$45 per issue or article

#### Site License Inquiries:

E-mail: SubQuote@medicalletter.org  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.

Get Connected:    

Copyright 2022. ISSN 0025-732X

